Blue Wave Therapeutics (BWT) is a privately owned Swiss/Norwegian-based biotechnology company, founded in 2021 with the goal to develop treatments aiming at significantly improving survival of cancer patients based on its novel biopolymer-radionuclide targeting platform.

Cerebriu is automating radiology workflows with AI, starting with MRI for brain diagnostic imaging, empowering radiologists with optimized workflows, and bringing clinical intelligence at the point of imaging.Cerebriu currently collaborates with world’s largest MRI manufacturer and is CE-marked.

We have discovered a systemically administered peptide (tCRK) that homes to skin and skin wounds and created a recombinant, multi-functional, therapeutic fusion protein of tCRK peptide and decorin (DCN), a natural transforming growth factor-? (TGF-?) inhibitor and an integral protein of skin. Treatment of lethal skin disease, recessive dystrophic epidermolysis bullosa (RDEB) mice with systemically administered recombinant protein resulted in inhibition of fibrosis formation and TGF-? signaling in the skin and significant improvement in the survival of RDEB mice (more than w. any previously tested therapeutic) indicating the best-in-class position.

Despite decades with significant efforts in gene sequencing, there is a large medical need for better markers that can predict outcomes to improve personal medicine and increase likelihood of success in drug development. Digital pathology and deep learning are on the verge of a breakthrough in medicine and can meet this need. DoMore Diagnostics is uniquely positioned with protected and scalable technology based on top notch research, and being the first company to obtain CE Mark for a prognostic digital marker.

Envue Technologies empower scientists with a patent-pending solution for disruptive discoveries in Life Science, by providing the next-generation bioanalysis instrument. We are at the forefront to address the scientist’s global unmet need for a tool that generates data of tiny biomolecules like proteins, DNA, and RNA. Using a cutting-edge combination of nanotechnology and light we develop an instrument to study biological relevant molecules and nanoparticles without introducing modifications to increase reliability and efficiency.

Implexion uses an innovative and scientifically based approach, based on world-leading research, to treat life-style related diseases by designing pharmaceuticals that target the gut bacteria rather than the human cells. The company is entering lead optimization phase with its first candidate and is seeking financial partners to create a unique microbiome-based pharmaceutical development company.

Kipuwex is an easy-to-use light-weight IoT device which wirelessly, continuously, and digitally measures a plurality of clinically relevant physiological parameters vital to the assessment of human well-being and disease management. The physiological parameters can be monitored remotely anywhere, at any time, by health care professionals and home users with a mobile or web application. Kipuwex then converts physiological parameters with an algorithm into reliable measurements for healthcare professionals and home users.

Ledidi builds and delivers Ledidi Core, a collaborative end-to-end cloud solution that supports the entire workflow in research, from study design, data capture, real-time statistical analysis and graphical presentation. Ledidi Core is safe, intuitive and easy-to-use, and allows for unique collaborative scenarios across institutions and national borders throughout the entire research lifecycle. Ledidi has global ambitions, and have recently established a subsidiary in the UK and are planning a US expansion early next year.

We have a unique solution that provides insight into the cellular mechanisms underlying cholesterol-lowering drug activity in individual patients for high cholesterol. Our test will help the doctor to determine the optimal and personalized treatment strategy, to determine whether statins are enough or more effective treatment is needed, and skip inefficient trial-and-error approach that can normally take years. In result, patients can achieve their treatment goals faster and reduce cardiovascular risk that can in turn contribute to less morbidity and mortality.

Pephexia Therapeutics is a Danish biotechnology company working with the discovery and development of novel peptide-based pharmacotherapies for an effective and convenient treatment of cachexia, sarcopenia, and related diseases. We are focusing on a dual agonistic peptide for the treatment of cancer cachexia and are in the lead optimization phase.

We are creating breakthroughs in diagnostic device development, utilising a re-usable detection technology with a positive impact on both the environment and the end-user. Our initial focus is on upgrading the pregnancy test through the development of a reusable test device that is easy to interpret, hygienic to use, and 99% accurate at the day of expected menstruation. In turn, this increases convenience-levels, reduces customer spendings on their reproductive health, minimises the risk of misinterpreting the test results, and is beneficial for the environment.

ResoTher Pharma is a clinical stage biotech company on a mission to improve patient outcomes in serious and life-threatening cardiovascular disorders such as myocardial infarction, stroke and heart failure. Our peptide drug candidates work by potently inducing resolution of inflammation and are targeted towards in-hospital, critical care indications. Our lead asset, RTP-026, is poised for proof of principle testing in myocardial infarct patients, to commence in Q1 2023.

Sartar develops a first-in-class targeted therapy for Soft Tissue Sarcomas, orphan cancers with high unmet medical need. Our approach is based on the discovery of phosphodiesterase 3 (PDE3) enzymes as novel oncogenes and repositioning of anagrelide with a unique long-acting formulation.

Sonai is re-inventing heart diagnostics. We utilize patented sensor technology, cloud service and machine learning to bring special care diagnostics into primary care. The Team has strong knowledge in scientific innovations, medicine and business.

From the Sortilins family of receptors, Teitur has developed cyclic peptides with a unique potential for addressing key pathologies across several neurodegenerative disorders including Huntington’s Disease, Parkinson’s Disease and Frontotemporal Dementia. Via subcutaneous delivery, the peptide has shown in vivo PoC across different models and is ready for IND development. Teitur is currently in discussions with investors to set up a syndicate that can support this program to PoC in humans.